Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open‐label, multicenter study
Overall, OB756 was well-tolerated and demonstrated acceptable efficacy, offering a promising therapeutic option for ET patients who are resistant to or intolerant of hydroxyurea or intolerant of interferon.
Authors
- Jie Jin (ORCID: https://orcid.org/0000-0002-8166-9915)
- Rumeng Li (ORCID: https://orcid.org/0000-0001-7735-6089)
- Jian Huang (ORCID: https://orcid.org/0000-0003-4200-8636)
- Zongjiu Jiao
- Hu Zhou (ORCID: https://orcid.org/0000-0001-5259-1429)
- Feng Zhang (ORCID: https://orcid.org/0000-0002-7845-7970)
- Lidong Zhao
- Qianshi Liu (ORCID: https://orcid.org/0009-0000-1607-1741)
- Tiejun Gong
- Lihong Shou (ORCID: https://orcid.org/0009-0002-2900-4024)
- Guo-Cai Wu (ORCID: https://orcid.org/0000-0001-5139-3877)
- Pengxiang Guo (ORCID: https://orcid.org/0000-0002-2176-3272)
- Lili Chen (ORCID: https://orcid.org/0000-0002-9965-8990)
- Yi Zhang (ORCID: https://orcid.org/0000-0003-3625-2288)
- Yile Zhou
Institutions
- Hebei Medical University (CN)
- Harbin Medical University (CN)
- Zhengzhou University (CN)
- Central People's Hospital of Zhanjiang (CN)
- Huzhou Central Hospital (CN)
- Xingtai People's Hospital (CN)
- The First People’s Hospital of Lianyungang (CN)
- Henan Cancer Hospital (CN)
- Taizhou First People's Hospital (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- Guizhou Provincial People's Hospital (CN)
- First Affiliated Hospital of Harbin Medical University (CN)
- First Affiliated Hospital of Hebei Medical University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1002/cncr.70101
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00